3. The ASCERTAIN Study. Source Holdaas H, Rostaing L, Serón D, et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor.

Slides:

Advertisements

Similar presentations

A Comparison of Early Versus Late Initiation of Renal Replacement Therapy in Critically III Patients with Acute Kidney Injury: A Systematic Review and.

Advertisements

REMEDIAL II Renal Insufficiency Following Contrast Media Administration Trial II (REMEDIAL II): RenalGuard™ System In High-Risk Patients for Contrast-Induced.

Everolimus plus Reduced-Exposure CsA is as Effi cacious as Mycophenolic Acid plus Standard-Exposure CsA Reference: Silva Jr HT, Cibrik D, Johnston T, et.

CN-1 Everolimus Renal Safety and Efficacy Extrapolations, Dose Recommendations Lawrence Hunsicker, MD Professor of Medicine and Medical Director of Organ.

Conversion from CNI to sirolimus Byung Chul Shin Division of Nephrology Chosun University Hospital, Gwangju.

30-Year Retrospective on Organ Transplant Immunosuppression in the Era of Calcineurin Inhibitors Herwig-Ulf Meier-Kriesche, MD Professor of Medicine Department.

© 2014 Direct One Communications, Inc. All rights reserved. 1 Belatacept: An Update of Ongoing Clinical Trials Michael D. Rizzari, MD University of Wisconsin–Madison.

TELBIVUDINE IS ASSOCIATED WITH IMPROVEMENT OF RENAL FUNCTION IN PATIENTS AFTER LIVER TRANSPLANTATION 1 Maria Ioannidou, 1 Evangelos Cholongitas, 2 Themistoklis.

The efFects of Pharmacological management of lipids in patients with CKD Andrew Monson FY1 18/9/14.

Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.

Calcineurin Inhibitor Toxicity In Kidney Allograft Protocol Biopsies Neeraja Kambham M.D. Stanford University.

Tuesday Clinical Case Conference Zae Kim. Therapy of ANCA-Associated Small Vessel Vasculitis.

TELBIVUDINE FOR THE TREATMENT OF CHRONIC HEPATITIS B: A CASE SERIES N.K. Gatselis, K. Zachou, E.I. Rigopoulou, G. Papadamou, K. Galanis G.N. Dalekos Department.

Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.

Rituximab for the Treatment of Rheumatoid Arthritis

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.

Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP 

Target Study Cardiac resynchronization therapy (CRT) is an established treatment for advanced heart failure symptoms, impaired LV systolic function, and.

Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.

Rapamune® Cyclosporine Withdrawal in Renal Transplantation Advisory Committee 1/24/02 Rosemary Tiernan, MD, MPH.

Study of cytokine gene polymorphism and graft outcome in live-donor kidney transplantation By Rashad Hassan MD Amgad El-Agroudy, Ahmad Hamdy, Amani Mostafa.

Changes in Renal Function in Patients Treated with Tenofovir DF (TDF) Compared to Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Joel E. Gallant,

RAPAMUNE ® TM 1 Randomization Variable Day* to Day 386 Randomization Variable Day* to Day 386 RAPA, C min, TN0.765 CsA, C min, TN0.201 Gender0.117 Increasing.

CR-1 Everolimus Benefit/Risk Assessment Howard J. Eisen, MD Thomas J. Vischer Professor of Medicine Chief, Division of Cardiology Drexel University College.

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

© 2014 Direct One Communications, Inc. All rights reserved. 1 How to Maximize Outcomes and Minimize Graft Failure Thin Thin Maw, MBBS Washington University.

Addenbrooke’s Hospital Rosie Hospital INTRODUCTION The cumulative incidence of chronic renal impairment in intestinal transplantation is 0.25 at 72 months;

Histological markers of CNI nephrotoxicity: Specific or not specific? Marion Rabant MD, Renaud Snanoudj MD, Virginie Royal MD, C. Girardin, E.Morelon MD.

A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

TM RAPAMUNE ® O-1 RAPAMUNE ® Overview John F. Neylan, MD Vice President, Transplantation Immunology Clinical Research and Development Wyeth-Ayerst Research.

Manufacturer: AstraZeneca FDA Approval Date: December 22, 2015

Therapeutic Hypothermia in Deceased Organ Donors and Kidney-Graft Function R3 김동연 /Prof. 정경환 N Engl J Med 373;5 July 30, 2015.

Introduction Conclusions Liver transplant recipients with impaired renal function or a low dose-adjusted tacrolimus concentration suggesting a high CYP3A4.

The DVD Trial. Source Reinecke H, Fobker M, Wellmann J, et al. A randomized controlled trial comparing hydration therapy to additional hemodialysis or.

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Elective Intra-aortic Balloon Counterpulsation During.

Thymoglobulin: An Overview of Its Performance in Clinical Trials as an Agent for the Induction Therapy Reference: Osama Gaber A, Knight RJ, Patel S, et.

The CONVERT Trial Source: Alberú J, Pascoe MD, Campistol JM, et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based,

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

History of Kidney Transplantation

The FRET Study Source: Inoue T, Ikeda H, Nakamura T, et al. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin.

The GREAT Trial. The Grampian Region Early Anistreplase Trial Reference Zahringer M, Sapoval M, Pattynama PM, et al. Sirolimus-eluting versus bare-metal.

Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.

The FAVORIT Study (Folic Acid for Vascular Outcome Reduction in Transplantation) Source Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering.

Everolimus for Advanced Pancreatic Neuroendocrine Tumors N Engl J Med 2011;364: R4. 박선희 / Prof. 동석호.

Kidney Graft Survival Rates do not improve by era: the impact of factor “Age” E. Bertoni MD, A. Larti MD, G. Rosso MD and M. Salvadori MD Renal Unit –

Sample Journal Club Your Name Here.

The ALERT Trial.

Effects of Uric acid- lowering therapy on renal outcomes: a systematic review and meta-analysis Nephrol Dial Transplant (2014) 29: Vaughan Washco.

Key publication slides

Neal B, et al. Diabetes Care 2015;38:403–411

LDV/SOF in kidney transplant recipients

Goede V et al. Proc ASH 2014;Abstract 3327.

m-TOR inhibitors: What role in liver transplantation?

Harrison CN et al. Proc ASH 2015;Abstract 59.

The MDRD Study.

m-TOR inhibitors: What role in liver transplantation?

Barrios C et al. SABCS 2009;Abstract 46.

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

Regulatory T cells and cancer: an undesired tolerance

Volume 79, Issue 8, Pages (April 2011)

Patient characteristics: American vs Canadian transplant patients

Risk factor Treatment GFR at baseline GFR at 5 years p Cadaveric donor

Immunosuppression in liver transplant recipients with renal impairment

m-TOR inhibitors: What role in liver transplantation?

Volume 67, Issue 4, Pages (April 2005)

Volume 68, Issue 4, Pages (October 2005)

Presentation transcript:

3. The ASCERTAIN Study

Source Holdaas H, Rostaing L, Serón D, et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation. 2011;92(4): 410–418.

Background Calcineurin inhibitor (CNI) therapy is known to induce nephrotoxicity in a dose-dependent manner. Nevertheless, improvements in graft function following elimination or reduction of CNI exposure in long-term kidney transplant recipients remains unclear. Furthermore, benefits of conversion from CNI to mammalian target of rapamycin inhibitor-based immunosuppression in long-term kidney transplant patients remain uncertain. The current study addressed this hypothesis.

Aim The ASCERTAIN study was undertaken to determine improvements in graft function in renal transplant patients with renal impairment following introduction of everolimus with elimination or minimization of CNI.

Methods

Key results Differences between CNI elimination (1.12 mL/min/1.73 m 2, 95% confidence interval [CI]: to 5.76, P=0.63) and CNI minimization (0.59 mL/min/1.73 m 2, 95% CI: to 5.07, P=0.79) vs controls at month 24 were non-significant. Post hoc analyses showed that patients with baseline creatinine clearance more than 50 mL/min had a significantly greater increase in measured GFR after CNI elimination vs controls. Adverse events resulted in discontinuation in 36 (28.3%) CNI elimination patients, 24 (16.7%) CNI minimization patients, and 5 (4.1%) controls (P<0.001 vs CNI elimination; P=0.020 vs CNI minimization).

Conclusion Conversion to everolimus with CNI elimination or minimization had no overall renal benefit and was associated with more frequent adverse events and discontinuations. Patients with a creatinine clearance of more than 50 mL/min may benefit from a change in therapy administered 6 months after renal transplantation. Conversion to everolimus with CNI elimination or minimization had no overall renal benefit.